Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats

British Journal of Pharmacology

Volumn 163, Issue 7, 2011, Pages 1550-1562

  Fattore, L ^a,b   Spano, M S ^c   Melis, V ^c,d   Fadda, P ^b,c   Fratta, W ^b,c  

^a Institute of Neuroscience Cagliari   (Italy)

^b Centre of Excellence Neurobiology of Dependence   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cannabinoid CB 1 receptor; craving incubation; drug substitution; drug seeking; naloxone; opioid; reinstatement; rimonabant; self administration

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; DIAMORPHINE; NALOXONE; RIMONABANT; CANNABINOID; CANNABINOID 1 RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; HEROIN DEPENDENCE; MONOTHERAPY; NONHUMAN; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; RAT; REINFORCEMENT; WITHDRAWAL SYNDROME; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SEEKING BEHAVIOR; LOCOMOTION; MALE;

ANALGESICS, OPIOID; ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; BENZOXAZINES; CANNABINOIDS; DRUG SUBSTITUTION; DRUG SYNERGISM; HEROIN; MALE; MORPHOLINES; NALOXONE; NAPHTHALENES; NARCOTIC ANTAGONISTS; PIPERIDINES; PYRAZOLES; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID; REINFORCEMENT SCHEDULE; SELF ADMINISTRATION;

EID: 79960338909     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01459.x     Document Type: Article

References (57)

1. Alexander SPH, Mathie A, Peters JA, (2009). Guide to Receptors and Channels (GRAC), 4th edn. Br J Pharmacol 158 (Suppl. 1): S1-S254.
2. Bienkowski P, Rogowski A, Korkosz A, Mierzejewski P, Radwanska K, Kaczmarek L, et al,. (2004). Time-dependent changes in alcohol-seeking behaviour during abstinence. Eur Neuropsychopharmacol 14: 355-360. (Pubitemid 39141676)
3. Bolger GT, Skolnick P, Rice KC, Weissman BA, (1988). Differential regulation of mu-opiate receptors in heroin- and morphine-dependent rats. FEBS Lett 234: 22-26.
4. Butler RK, Rea K, Lang Y, Gavin AM, Finn DP, (2008). Endocannabinoid- mediated enhancement of fear-conditioned analgesia in rats: opioid receptor dependency and molecular correlates. Pain 140: 491-500.
5. Caillé S, Parsons LH, (2006). Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology 31: 804-813.
6. Carrera MR, Schulteis G, Koob GF, (1999). Heroin self-administration in dependent Wistar rats: increased sensitivity to naloxone. Psychopharmacology 144: 111-120. (Pubitemid 29264426)
7. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL, (1990). Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102: 156-162. (Pubitemid 20264653)
8. Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P, et al,. (2007). Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropharmacology 52: 646-654. (Pubitemid 46151687)
9. De Vries TJ, Schoffelmeer AN, (2005). Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26: 420-426. (Pubitemid 41039218)
10. De Vries TJ, Homberg JR, Binnekade R, Raasø H, Schoffelmeer AN, (2003). Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 168: 164-169. (Pubitemid 36851175)
11. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L, et al,. (2006). Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 17: 1629-1632. (Pubitemid 44454770)
12. Fattore L, Cossu G, Martellotta MC, Fratta W, (2001). Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology 156: 410-416. (Pubitemid 32695850)
13. Fattore L, Spano MS, Cossu G, Deiana S, Fratta W, (2003). Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. Eur J Neurosci 17: 1723-1726. (Pubitemid 36628140)
14. Fattore L, Cossu G, Spano MS, Deiana S, Fadda P, Scherma M, et al,. (2004). Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 16: 147-158. (Pubitemid 39586913)
15. Fattore L, Deiana S, Spano MS, Cossu G, Fadda P, Scherma M, et al,. (2005a). Endocannabinoid system and opioid addiction: behavioural aspects. Pharmacol Biochem Behav 81: 343-359. (Pubitemid 40807132)
16. Fattore L, Spano MS, Cossu G, Deiana S, Fadda P, Fratta W, (2005b). Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats. Neuropharmacology 48: 1097-1104. (Pubitemid 40725982)
17. Fattore L, Fadda P, Fratta W, (2007a). Endocannabinoid regulation of relapse mechanisms. Pharmacol Res 56: 418-427. (Pubitemid 350026394)
18. Fattore L, Spano MS, Deiana S, Melis V, Cossu G, Fadda P, et al,. (2007b). An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. Brain Res Rev 53: 1-16. (Pubitemid 44854208)
19. Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W, (2007c). Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol 152: 795-804. (Pubitemid 350034986)
20. Fattore L, Viganò D, Fadda P, Rubino T, Fratta W, Parolaro D, (2007d). Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci 25: 2191-2200. (Pubitemid 46581742)
21. Fattore L, Spano MS, Altea S, Fadda P, Fratta W, (2010). Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones. Br J Pharmacol 160: 724-735.
22. Greaven D, Greaven K, (1983). Treated and untreated addicts: factors associated with treatment and cessation of heroin use. J Drug Issues 13: 207-218.
23. Grimm JW, Hope BT, Wise RA, Shaham Y, (2001). Neuroadaptation. Incubation of cocaine craving after withdrawal. Nature 412: 141-142. (Pubitemid 32674700)
24. Hoffman AF, Oz M, Caulder T, Lupica CR, (2003). Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 23: 4815-4820. (Pubitemid 36793206)
25. Kuntz KL, Twining RC, Baldwin AE, Vrana KE, Grigson PS, (2008). Heroin self-administration: I. Incubation of goal-directed behavior in rats. Pharmacol Biochem Behav 90: 344-348.
26. Kuntz-Melcavage KL, Brucklacher RM, Grigson PS, Freeman WM, Vrana KE, (2009). Gene expression changes following extinction testing in a heroin behavioral incubation model. BMC Neurosci 10: 95-105.
27. Lane DA, Chan J, Lupica CR, Pickel VM, (2010). Cannabinoid-1 receptor gene deletion has a compartment-specific affect on the dendritic and axonal availability of μ-opioid receptors and on dopamine axons in the mouse nucleus accumbens. Synapse 64: 886-897.
28. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al,. (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283: 401-404.
29. Li YQ, Li FQ, Wang XY, Wu P, Zhao M, Xu CM, et al,. (2008). Central amygdala extracellular signal-regulated kinase signaling pathway is critical to incubation of opiate craving. J Neurosci 28: 13248-13257.
30. Manzanares J, Corchero J, Romero J, Fernández-Ruiz JJ, Ramos JA, Fuentes JA, (1999). Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 20: 287-294. (Pubitemid 29301682)
31. Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W, (1998). Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. Neuroscience 85: 327-330. (Pubitemid 28218655)
32. Martin M, Ledent C, Parmentier M, Maldonado R, Valverde O, (2000). Cocaine, but not morphine, induces conditioned place preference and sensitization to locomotor responses in CB1 knockout mice. Eur J Neurosci 12: 4038-4046.
33. Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, et al,. (2001). Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction. Br J Pharmacol 132: 1809-1816. (Pubitemid 32397973)
34. Nava F, Manzato E, Lucchini A, (2007). Chronic cannabis use does not affect the normalization of hypothalamic-pituitary-adrenal (HPA) axis induced by methadone in heroin addicts. Prog Neuropsychopharmacol Biol Psychiatry 31: 1089-1094. (Pubitemid 46810101)
35. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al,. (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 21: 5344-5350. (Pubitemid 32622960)
36. Negus SS, Henriksen SJ, Mattox A, Pasternak GW, Portoghese PS, Takemori AE, et al,. (1993). Effect of antagonists selective for mu, delta and kappa opioid receptors on the reinforcing effects of heroin in rats. J Pharmacol Exp Ther 265: 1245-1252. (Pubitemid 23321026)
37. Noble A, Best D, Man LH, Gossop M, Stang J, (2002). Self-detoxification attempts among methadone maintenance patients: what methods and what success? Addict Behav 27: 575-584. (Pubitemid 34763817)
38. O'Brien CP, (2005). Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 162: 1423-1431. (Pubitemid 41105556)
39. Pickel VM, Chan J, Kash TL, Rodríguez JJ, MacKie K, (2004). Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience 127: 101-112. (Pubitemid 38829156)
40. Robledo P, Berrendero F, Ozaita A, Maldonado R, (2008). Advances in the field of cannabinoid-opioid cross-talk. Addict Biol 13: 213-224. (Pubitemid 351692983)
41. Rodriguez JJ, Mackie K, Pickel VM, (2001). Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 21: 823-833. (Pubitemid 32163123)
42. Rogers JL, Ghee S, See RE, (2008). The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse. Neuroscience 151: 579-588.
43. Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M, (2001). CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 12: 3689-3692. (Pubitemid 33105152)
44. Schoffelmeer AN, Hogenboom F, Wardeh G, De Vries TJ, (2006). Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51: 773-781. (Pubitemid 44308340)
45. Seivewright N, (2003). Methadone treatment outcomes appear mainly unaffected by cannabis use. Addiction 98: 251-252. (Pubitemid 36269562)
46. Shalev U, Morales M, Hope B, Yap J, Shaham Y, (2001). Time-dependent changes in extinction behavior and stress-induced reinstatement of drug seeking following withdrawal from heroin in rats. Psychopharmacology 156: 98-107. (Pubitemid 32646331)
47. Shapira M, Gafni M, Sarne Y, (2003). Long-term interactions between opioid and cannabinoid agonists at the cellular level: cross-desensitization and downregulation. Brain Res 960: 190-200. (Pubitemid 36044576)
48. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR, (2003). The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306: 93-102. (Pubitemid 36734361)
49. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, Goldberg SR, (2005). Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30: 2046-2057. (Pubitemid 43093504)
50. Solinas M, Scherma M, Fattore L, Stroik J, Wertheim C, Tanda G, et al,. (2007). Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. J Neurosci 27: 5615-5620. (Pubitemid 350021063)
51. Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, Fratta W, (2004). CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. Br J Pharmacol 143: 343-350. (Pubitemid 39424822)
52. Spano MS, Fattore L, Fratta W, Fadda P, (2007). The GABAB receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology 52: 1555-1562. (Pubitemid 46695739)
53. Tanda G, Pontieri FE, Di Chiara G, (1997). Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276: 2048-2050. (Pubitemid 27443611)
54. Tran-Nguyen LT, Fuchs RA, Coffey GP, Baker DA, O'Dell LE, Neisewander JL, (1998). Time-dependent changes in cocaine-seeking behavior and extracellular dopamine levels in the amygdala during cocaine withdrawal. Neuropsychopharmacology 19: 48-59. (Pubitemid 28255213)
55. Trezza V, Vanderschuren LJ, (2008). Cannabinoid and opioid modulation of social play behavior in adolescent rats: differential behavioral mechanisms. Eur Neuropsychopharmacol 18: 519-530.
56. Viganò D, Rubino T, Parolaro D, (2005). Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 81: 360-368. (Pubitemid 40807133)
57. Weizman T, Gelkopf M, Melamed Y, Adelson M, Bleich A, (2004). Cannabis use is not a risk factor for treatment outcome in methadone maintenance treatment: a 1-year prospective study in an Israeli clinic. Aust N Z J Psychiatry 38: 42-46. (Pubitemid 38443677)